Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
International Journal of Medical & Pharmaceutical Sciences · September 7, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence that GLP-1 receptor agonists, particularly liraglutide and semaglutide, achieve clinically meaningful weight reduction and cardiometabolic improvements in adults with overweight or obesity, with or without type 2 diabetes. The authors conclude GLP-1 RAs represent a major advance in obesity management, contingent on individualized selection, ongoing monitoring, and integration with lifestyle intervention, while acknowledging heterogeneous response, gastrointestinal tolerability concerns, and post-discontinuation weight regain.
Journal article.
Pivotal trials of liraglutide and semaglutide demonstrate clinically meaningful reductions in body weight Weight reduction accompanied by improvements in glycaemic control, cardiometabolic risk factors, physical function and quality of life Treatment response is heterogeneous with important concerns regarding gastrointestinal adverse effects, treatment discontinuation, and weight regain after withdrawal
Treatment response is heterogeneous with important concerns regarding gastrointestinal adverse effects, treatment discontinuation, and weight regain after withdrawal
The source did not state who this applies to in practice.
A narrative review synthesizing evidence from pivotal trials to evaluate GLP-1 receptor agonists for weight management, offering clinical recommendations rather than reporting original research.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is a chronic, relapsing metabolic disease associated with substantial morbidity, mortality and healthcare burden. Although dietary modification, physical activity and behavioural therapy remain fundamental to treatment, long-term maintenance of clinically meaningful weight loss is difficult for many individuals. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed for type 2 diabetes mellitus but have become major pharmacological options for chronic weight management because they reduce appetite, increase satiety, delay gastric emptying and improve glucose-dependent metabolic regulation. This review evaluates the efficacy of GLP-1-based therapies for weight management in adults with overweight or obesity, with particular attention to differences between populations with and without type 2 diabetes. Evidence from pivotal trials of liraglutide and semaglutide demonstrates clinically meaningful reductions in body weight, while newer incretin-based approaches have broadened the therapeutic landscape. Weight reduction is accompanied by improvements in glycaemic control, cardiometabolic risk factors, physical function and health-related quality of life. However, treatment response is heterogeneous and important concerns remain regarding gastrointestinal adverse effects, treatment discontinuation, weight regain after withdrawal, preservation of lean mass, long-term adherence, affordability and access. Lifestyle intervention remains an essential component of pharmacotherapy. Overall, GLP-1 RAs represent a major advance in obesity management, but optimal outcomes require individualized patient selection, ongoing safety monitoring and long-term multidisciplinary care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.